[96a5a0]: / output / allTrials / identified / NCT05667194_identified.json

Download this file

868 lines (868 with data), 39.9 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
{
"info": {
"nct_id": "NCT05667194",
"official_title": "A Phase 1 Study to Assess the Safety ,Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of KH617 After SAD and MAD Administration for Patients With Advanced Solid Tumors",
"inclusion_criteria": "* 1.Signed and dated written informed consent in accordance with International Council for Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.\n\n 2.Patient is male or female ≥18 years of age. 3.Patient must satisfy the following laboratory test results:\n\n a.Hemoglobin ≥9g/dL b.Platelet count ≥100×10^9/L c.Absolute neutrophil count≥1.5×10^9/L d.Albumin ≥3.0g/dL e.Total bilirubin ≤1.5×ULN f.Aspartate aminotransferase and alanine aminotransferase≤2.5×ULN g.Adequate renal function, defined as estimated serum creatinine clearance>50mL/minute calculated using the Cockcroft-Gault equation,urine protein<2+ or urine protein>2+ but 24-hour proteinuria<1g h.Prothrombin time, international normalized ratio, and activated partial thromboplastin time≤1.5×ULN (except for patients receiving anticoagulant therapy) 4.Patients who have fully recovered (defined as ≤grade 1 NCI-CTCAE 5.0) from all previous acute treatment-related toxic effects of previous cancer treatments prior to enrollment.\n\n 5.Life expectancy at least 3 months. 6.Specific Inclusion Criteria\n 1. Advanced Solid Tumors\n\n 1. Patients with histopathology and/or cytology diagnosed as unresectable, locally advanced or metastatic malignant solid tumors for which there is no further standard treatment or for which the patient is not tolerated.\n 2. Patient has at least one measurable or evaluable target lesion by RECIST 1.1.\n 3. Patient has an ECOG status of 0 to 2.\n 2. Brain Metastases\n\n 1. Patient has at least one measurable or evaluable target lesion by RANO-BM.\n 3. rGBM\n\n 1. Patient with histopathology and/or cytology diagnosed advanced malignant adult diffuse glioma has unequivocal evidence of GBM recurrence/progression following completion of standard treatment.\n 2. Patient has at measurable or evaluable target lesion by RANO.\n 3. 4.Patient has a Karnofsky Performance score (KPS) ≥60.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* 1.Patient has received extensive radiation therapy. 2.Patients has the following infectious diseases:\n\n a.Hepatitis B surface antigen-positive and HBV-DNA test indicated active hepatitis B b.Active hepatitis c. C. AIDS or HIV antibody test is positive. d.Uncontrolled active infection. 3. Patient has a positive blood beta-HCG pregnancy test 7 days before the first administration (only for female with bearing potential ), or male and female with bearing potential who are unwilling to use adequate contraception for the duration of the study, and for a minimum of6 months after last dose of KH617.\n\n 4. 11.Patient is currently pregnant or breastfeeding. 5. Patients with previous phrenoblabia history or currently phrenoblabia Including but not limited to schizophrenia, paranoia, phobias, obsessive-compulsive disorder, insomnia, Alzheimer's disease, behavioral volitional disorder, postpartum mental disorder, paranoid mental disorder, or organic psychosis.\n\n 6. Patient has had another malignancy within the previous 5 years. 7. Patient has active cardiac or cerebrovascular disease. 8.Patient has participated in another investigational study using an investigational or marketed drug or device within 28 days.\n\n 9. Patient has severe sensitivity/allergic reaction to KH617. 10.Patient has any other conditions that render them inappropriate for inclusion in the investigator's opinion.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* 1.Signed and dated written informed consent in accordance with International Council for Harmonisation - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.",
"criterions": [
{
"exact_snippets": "Signed and dated written informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "in accordance with International Council for Harmonisation - Good Clinical Practice (ICH-GCP)",
"criterion": "compliance with ICH-GCP",
"requirements": [
{
"requirement_type": "compliance",
"expected_value": true
}
]
},
{
"exact_snippets": "local legislation",
"criterion": "compliance with local legislation",
"requirements": [
{
"requirement_type": "compliance",
"expected_value": true
}
]
}
]
},
{
"line": "2.Patient is male or female ≥18 years of age. 3.Patient must satisfy the following laboratory test results:",
"criterions": [
{
"exact_snippets": "Patient is male or female",
"criterion": "gender",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"male",
"female"
]
}
]
},
{
"exact_snippets": "≥18 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "a.Hemoglobin ≥9g/dL b.Platelet count ≥100×10^9/L c.Absolute neutrophil count≥1.5×10^9/L d.Albumin ≥3.0g/dL e.Total bilirubin ≤1.5×ULN f.Aspartate aminotransferase and alanine aminotransferase≤2.5×ULN g.Adequate renal function, defined as estimated serum creatinine clearance>50mL/minute calculated using the Cockcroft-Gault equation,urine protein<2+ or urine protein>2+ but 24-hour proteinuria<1g h.Prothrombin time, international normalized ratio, and activated partial thromboplastin time≤1.5×ULN (except for patients receiving anticoagulant therapy) 4.Patients who have fully recovered (defined as ≤grade 1 NCI-CTCAE 5.0) from all previous acute treatment-related toxic effects of previous cancer treatments prior to enrollment.",
"criterions": [
{
"exact_snippets": "Hemoglobin ≥9g/dL",
"criterion": "hemoglobin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 9,
"unit": "g/dL"
}
}
]
},
{
"exact_snippets": "Platelet count ≥100×10^9/L",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">=",
"value": 100,
"unit": "×10^9/L"
}
}
]
},
{
"exact_snippets": "Absolute neutrophil count≥1.5×10^9/L",
"criterion": "absolute neutrophil count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">=",
"value": 1.5,
"unit": "×10^9/L"
}
}
]
},
{
"exact_snippets": "Albumin ≥3.0g/dL",
"criterion": "albumin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": ">=",
"value": 3.0,
"unit": "g/dL"
}
}
]
},
{
"exact_snippets": "Total bilirubin ≤1.5×ULN",
"criterion": "total bilirubin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "×ULN"
}
}
]
},
{
"exact_snippets": "Aspartate aminotransferase and alanine aminotransferase≤2.5×ULN",
"criterion": "aspartate aminotransferase and alanine aminotransferase levels",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2.5,
"unit": "×ULN"
}
}
]
},
{
"exact_snippets": "Adequate renal function, defined as estimated serum creatinine clearance>50mL/minute calculated using the Cockcroft-Gault equation",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "creatinine clearance",
"expected_value": {
"operator": ">",
"value": 50,
"unit": "mL/minute"
}
}
]
},
{
"exact_snippets": "urine protein<2+ or urine protein>2+ but 24-hour proteinuria<1g",
"criterion": "urine protein",
"requirements": [
{
"requirement_type": "level",
"expected_value": [
"<2+",
"24-hour proteinuria<1g"
]
}
]
},
{
"exact_snippets": "Prothrombin time, international normalized ratio, and activated partial thromboplastin time≤1.5×ULN (except for patients receiving anticoagulant therapy)",
"criterion": "coagulation times",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.5,
"unit": "×ULN"
}
}
]
},
{
"exact_snippets": "Patients who have fully recovered (defined as ≤grade 1 NCI-CTCAE 5.0) from all previous acute treatment-related toxic effects of previous cancer treatments prior to enrollment",
"criterion": "recovery from previous treatment-related toxic effects",
"requirements": [
{
"requirement_type": "recovery",
"expected_value": "≤grade 1 NCI-CTCAE 5.0"
}
]
}
]
},
{
"line": "5.Life expectancy at least 3 months. 6.Specific Inclusion Criteria",
"criterions": [
{
"exact_snippets": "Life expectancy at least 3 months",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "1. Advanced Solid Tumors",
"criterions": [
{
"exact_snippets": "Advanced Solid Tumors",
"criterion": "solid tumors",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "advanced"
}
]
}
]
},
{
"line": "1. Patients with histopathology and/or cytology diagnosed as unresectable, locally advanced or metastatic malignant solid tumors for which there is no further standard treatment or for which the patient is not tolerated.",
"criterions": [
{
"exact_snippets": "histopathology and/or cytology diagnosed",
"criterion": "diagnosis method",
"requirements": [
{
"requirement_type": "method",
"expected_value": [
"histopathology",
"cytology"
]
}
]
},
{
"exact_snippets": "unresectable, locally advanced or metastatic malignant solid tumors",
"criterion": "tumor status",
"requirements": [
{
"requirement_type": "resectability",
"expected_value": false
},
{
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
},
{
"requirement_type": "malignancy",
"expected_value": true
}
]
},
{
"exact_snippets": "for which there is no further standard treatment",
"criterion": "treatment options",
"requirements": [
{
"requirement_type": "availability",
"expected_value": false
}
]
},
{
"exact_snippets": "for which the patient is not tolerated",
"criterion": "treatment tolerance",
"requirements": [
{
"requirement_type": "tolerance",
"expected_value": false
}
]
}
]
},
{
"line": "2. Patient has at least one measurable or evaluable target lesion by RECIST 1.1.",
"criterions": [
{
"exact_snippets": "Patient has at least one measurable or evaluable target lesion by RECIST 1.1.",
"criterion": "target lesion",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
},
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"evaluable"
]
},
{
"requirement_type": "evaluation criteria",
"expected_value": "RECIST 1.1"
}
]
}
]
},
{
"line": "3. Patient has an ECOG status of 0 to 2.",
"criterions": [
{
"exact_snippets": "ECOG status of 0 to 2",
"criterion": "ECOG status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "2. Brain Metastases",
"criterions": [
{
"exact_snippets": "Brain Metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "1. Patient has at least one measurable or evaluable target lesion by RANO-BM.",
"criterions": [
{
"exact_snippets": "Patient has at least one measurable or evaluable target lesion by RANO-BM.",
"criterion": "target lesion",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "N/A"
}
},
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"evaluable"
]
},
{
"requirement_type": "assessment method",
"expected_value": "RANO-BM"
}
]
}
]
},
{
"line": "3. rGBM",
"criterions": [
{
"exact_snippets": "rGBM",
"criterion": "recurrent glioblastoma multiforme (rGBM)",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "1. Patient with histopathology and/or cytology diagnosed advanced malignant adult diffuse glioma has unequivocal evidence of GBM recurrence/progression following completion of standard treatment.",
"criterions": [
{
"exact_snippets": "histopathology and/or cytology diagnosed advanced malignant adult diffuse glioma",
"criterion": "diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "advanced malignant adult diffuse glioma"
}
]
},
{
"exact_snippets": "unequivocal evidence of GBM recurrence/progression",
"criterion": "GBM recurrence/progression",
"requirements": [
{
"requirement_type": "evidence",
"expected_value": true
}
]
},
{
"exact_snippets": "following completion of standard treatment",
"criterion": "completion of standard treatment",
"requirements": [
{
"requirement_type": "completion",
"expected_value": true
}
]
}
]
},
{
"line": "2. Patient has at measurable or evaluable target lesion by RANO.",
"criterions": [
{
"exact_snippets": "measurable or evaluable target lesion by RANO",
"criterion": "target lesion",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": [
"measurable",
"evaluable"
]
}
]
}
]
},
{
"line": "3. 4.Patient has a Karnofsky Performance score (KPS) ≥60.",
"criterions": [
{
"exact_snippets": "Karnofsky Performance score (KPS) ≥60",
"criterion": "Karnofsky Performance score (KPS)",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* 1.Patient has received extensive radiation therapy. 2.Patients has the following infectious diseases:",
"criterions": [
{
"exact_snippets": "Patient has received extensive radiation therapy.",
"criterion": "radiation therapy",
"requirements": [
{
"requirement_type": "extent",
"expected_value": "extensive"
}
]
},
{
"exact_snippets": "Patients has the following infectious diseases:",
"criterion": "infectious diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "a.Hepatitis B surface antigen-positive and HBV-DNA test indicated active hepatitis B b.Active hepatitis c. C. AIDS or HIV antibody test is positive. d.Uncontrolled active infection. 3. Patient has a positive blood beta-HCG pregnancy test 7 days before the first administration (only for female with bearing potential ), or male and female with bearing potential who are unwilling to use adequate contraception for the duration of the study, and for a minimum of6 months after last dose of KH617.",
"criterions": [
{
"exact_snippets": "Hepatitis B surface antigen-positive",
"criterion": "Hepatitis B surface antigen",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "HBV-DNA test indicated active hepatitis B",
"criterion": "HBV-DNA test",
"requirements": [
{
"requirement_type": "indication",
"expected_value": "active hepatitis B"
}
]
},
{
"exact_snippets": "Active hepatitis c",
"criterion": "Hepatitis C",
"requirements": [
{
"requirement_type": "activity",
"expected_value": "active"
}
]
},
{
"exact_snippets": "AIDS or HIV antibody test is positive",
"criterion": "HIV antibody test",
"requirements": [
{
"requirement_type": "result",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "Uncontrolled active infection",
"criterion": "Infection",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
},
{
"requirement_type": "activity",
"expected_value": "active"
}
]
},
{
"exact_snippets": "Patient has a positive blood beta-HCG pregnancy test 7 days before the first administration",
"criterion": "Blood beta-HCG pregnancy test",
"requirements": [
{
"requirement_type": "result",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "female with bearing potential",
"criterion": "Female with childbearing potential",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "male and female with bearing potential who are unwilling to use adequate contraception for the duration of the study, and for a minimum of6 months after last dose of KH617",
"criterion": "Contraception use",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": "unwilling"
}
]
}
]
},
{
"line": "4. 11.Patient is currently pregnant or breastfeeding. 5. Patients with previous phrenoblabia history or currently phrenoblabia Including but not limited to schizophrenia, paranoia, phobias, obsessive-compulsive disorder, insomnia, Alzheimer's disease, behavioral volitional disorder, postpartum mental disorder, paranoid mental disorder, or organic psychosis.",
"criterions": [
{
"exact_snippets": "Patient is currently pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "current status",
"expected_value": false
}
]
},
{
"exact_snippets": "breastfeeding",
"criterion": "breastfeeding",
"requirements": [
{
"requirement_type": "current status",
"expected_value": false
}
]
},
{
"exact_snippets": "previous phrenoblabia history",
"criterion": "phrenoblabia history",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
},
{
"exact_snippets": "currently phrenoblabia",
"criterion": "current phrenoblabia",
"requirements": [
{
"requirement_type": "current status",
"expected_value": false
}
]
},
{
"exact_snippets": "schizophrenia",
"criterion": "schizophrenia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "paranoia",
"criterion": "paranoia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "phobias",
"criterion": "phobias",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "obsessive-compulsive disorder",
"criterion": "obsessive-compulsive disorder",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "insomnia",
"criterion": "insomnia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Alzheimer's disease",
"criterion": "Alzheimer's disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "behavioral volitional disorder",
"criterion": "behavioral volitional disorder",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "postpartum mental disorder",
"criterion": "postpartum mental disorder",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "paranoid mental disorder",
"criterion": "paranoid mental disorder",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "organic psychosis",
"criterion": "organic psychosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "6. Patient has had another malignancy within the previous 5 years. 7. Patient has active cardiac or cerebrovascular disease. 8.Patient has participated in another investigational study using an investigational or marketed drug or device within 28 days.",
"criterions": [
{
"exact_snippets": "Patient has had another malignancy within the previous 5 years.",
"criterion": "another malignancy",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "years"
}
}
]
},
{
"exact_snippets": "Patient has active cardiac or cerebrovascular disease.",
"criterion": "active cardiac or cerebrovascular disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Patient has participated in another investigational study using an investigational or marketed drug or device within 28 days.",
"criterion": "participation in another investigational study",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 28,
"unit": "days"
}
}
]
}
]
},
{
"line": "9. Patient has severe sensitivity/allergic reaction to KH617. 10.Patient has any other conditions that render them inappropriate for inclusion in the investigator's opinion.",
"criterions": [
{
"exact_snippets": "Patient has severe sensitivity/allergic reaction to KH617.",
"criterion": "sensitivity/allergic reaction to KH617",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
},
{
"exact_snippets": "Patient has any other conditions that render them inappropriate for inclusion in the investigator's opinion.",
"criterion": "other conditions",
"requirements": [
{
"requirement_type": "appropriateness for inclusion",
"expected_value": "inappropriate in the investigator's opinion"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}